Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

A Anantharaman, EJ Small - Expert review of anticancer therapy, 2017 - Taylor & Francis
ABSTRACT Introduction: Prostate cancer (PCa) is currently the second most common
cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is …
被引用次数：36 相关文章

Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.

A Anantharaman, EJ Small - Expert Review of Anticancer Therapy, 2017 - europepmc.org
Prostate cancer (PCa) is currently the second most common cancer affecting men
worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is the incurable form of …

Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

A Anantharaman, EJ Small - Expert review of anticancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Prostate cancer (PCa) is currently the second most common cancer affecting men
worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is the incurable form of …

[引用][C] Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment

A Anantharaman, EJ Small - Expert Review of Anticancer Therapy, 2017 - cir.nii.ac.jp
Tackling non-metastatic castration-resistant prostate cancer: special considerations in
treatment | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …